STAT3 and melanoma: Ting Li have pointed out that IGFBP2 can regulate PD-L1 expression by activating EGFR-STAT3 signaling pathway in melanoma and participate in tumor immunotherapy resistance, but its specific mechanism needs to be further studied (31).